Efficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: a randomized controlled study

Table 3 Adjusted primary and secondary outcomes over the 12-week treatment period

		Significance for between group differences at follow-ups *
Outcome		0-6 wks	0-12 wks
Primary	WOMAC
	Pain	0.43	0.08
	Stiffness	0.23	0.08
	Function	0.85	0.04*
	Total	0.60	0.03*
	ALF	0.31	0.09
	SF-36	0.98	0.54
	VAS	0.06	0.05*
Secondary	KSKS	0.43	0.09
	KSFS	0.29	0.63

* The significance threshold was set at p ≤ 0.05.
WOMAC = Western Ontario and McMaster Osteoarthritis Index; ALF = Aggregated locomotor function; SF-36 = 36-item short-form health survey; VAS = Visual-analogue-scale for pain; KSKS = Knee society knee score; KSFS = Knee society function score.